Exact Sciences (EXAS) Competitors $53.81 +2.40 (+4.67%) Closing price 04:00 PM EasternExtended Trading$53.80 -0.01 (-0.02%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, INCY, NBIX, UTHR, BMRN, EXEL, MDGL, HALO, RGEN, and IONSShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen Incyte Neurocrine Biosciences United Therapeutics BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Ionis Pharmaceuticals Exact Sciences (NASDAQ:EXAS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends. Which has higher earnings & valuation, EXAS or BIIB? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.76B3.68-$1.03B-$5.43-9.89Biogen$9.68B2.14$1.63B$10.4613.51 Which has more risk and volatility, EXAS or BIIB? Exact Sciences has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Is EXAS or BIIB more profitable? Biogen has a net margin of 15.31% compared to Exact Sciences' net margin of -34.19%. Biogen's return on equity of 13.85% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-34.19% -1.75% -0.76% Biogen 15.31%13.85%8.32% Do analysts recommend EXAS or BIIB? Exact Sciences presently has a consensus price target of $67.05, suggesting a potential upside of 24.89%. Biogen has a consensus price target of $185.74, suggesting a potential upside of 31.44%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Exact Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.91Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34 Does the media prefer EXAS or BIIB? In the previous week, Biogen had 30 more articles in the media than Exact Sciences. MarketBeat recorded 44 mentions for Biogen and 14 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 1.11 beat Biogen's score of 1.07 indicating that Exact Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exact Sciences 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 26 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in EXAS or BIIB? 88.8% of Exact Sciences shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 1.2% of Exact Sciences shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryBiogen beats Exact Sciences on 9 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.16B$3.16B$5.77B$9.91BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-9.8821.1675.7426.65Price / Sales3.68473.88557.21121.56Price / Cash8.7545.1137.1158.92Price / Book4.149.8811.446.07Net Income-$1.03B-$53.47M$3.28B$266.32M7 Day Performance13.21%2.53%0.63%0.06%1 Month Performance13.36%8.25%6.89%3.90%1 Year Performance-11.86%13.27%59.40%23.68% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.7985 of 5 stars$53.81+4.7%$67.05+24.6%-10.0%$10.19B$2.76B-9.917,000Positive NewsShort Interest ↑BIIBBiogen4.8476 of 5 stars$132.22-0.3%$185.74+40.5%-31.7%$19.39B$9.68B12.647,605Trending NewsAnalyst ForecastINCYIncyte4.6614 of 5 stars$84.61+1.1%$81.60-3.6%+32.8%$16.52B$4.58B19.232,617Analyst ForecastShort Interest ↑NBIXNeurocrine Biosciences4.87 of 5 stars$139.60+0.5%$159.50+14.3%+14.6%$13.85B$2.36B41.301,800Positive NewsAnalyst ForecastShort Interest ↑UTHRUnited Therapeutics4.409 of 5 stars$304.76-0.8%$382.00+25.3%+7.7%$13.75B$2.88B11.901,305Trending NewsAnalyst ForecastInsider TradeShort Interest ↑BMRNBioMarin Pharmaceutical4.9942 of 5 stars$58.27+1.0%$93.17+59.9%-36.8%$11.19B$3.06B17.293,040Positive NewsAnalyst ForecastEXELExelixis4.8216 of 5 stars$37.42-1.3%$44.06+17.7%+46.0%$10.07B$2.23B17.991,147MDGLMadrigal Pharmaceuticals4.1598 of 5 stars$437.85+0.2%$459.25+4.9%+75.8%$9.72B$180.13M-34.0790Positive NewsAnalyst ForecastHALOHalozyme Therapeutics4.6859 of 5 stars$73.15+0.5%$67.11-8.3%+18.1%$8.56B$1.02B16.74390Trending NewsAnalyst UpgradeInsider TradeAnalyst RevisionRGENRepligen4.8635 of 5 stars$122.32+0.1%$169.45+38.5%-16.5%$6.88B$634.44M-489.261,778News CoveragePositive NewsAnalyst ForecastIONSIonis Pharmaceuticals4.2033 of 5 stars$42.63+0.0%$59.64+39.9%+24.6%$6.79B$705M-23.171,069Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies Biogen Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives United Therapeutics Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Repligen Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXAS Stock Alerts